When is RIGL's latest earnings report released?
The most recent financial report for Rigel pharmaceuticals, inc. (RIGL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RIGL's short-term business performance and financial health. For the latest updates on RIGL's earnings releases, visit this page regularly.
Where does RIGL fall in the P/E River chart?
According to historical valuation range analysis, Rigel pharmaceuticals, inc. (RIGL)'s current price-to-earnings (P/E) ratio is 1.66, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of RIGL?
According to the latest financial report, Rigel pharmaceuticals, inc. (RIGL) reported an Operating Profit of 23.17M with an Operating Margin of 33.19% this period, representing a growth of 39.12% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is RIGL's revenue growth?
In the latest financial report, Rigel pharmaceuticals, inc. (RIGL) announced revenue of 69.8M, with a Year-Over-Year growth rate of 21.19%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does RIGL have?
As of the end of the reporting period, Rigel pharmaceuticals, inc. (RIGL) had total debt of 53.3M, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does RIGL have?
At the end of the period, Rigel pharmaceuticals, inc. (RIGL) held Total Cash and Cash Equivalents of 40.58M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does RIGL go with three margins increasing?
In the latest report, Rigel pharmaceuticals, inc. (RIGL) achieved the “three margins increasing” benchmark, with a gross margin of 91.5%%, operating margin of 33.19%%, and net margin of 384%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RIGL's profit trajectory and future growth potential.
Is RIGL's EPS continuing to grow?
According to the past four quarterly reports, Rigel pharmaceuticals, inc. (RIGL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 14.88. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of RIGL?
Rigel pharmaceuticals, inc. (RIGL)'s Free Cash Flow (FCF) for the period is 21.99M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 51.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of RIGL?
The latest valuation data shows Rigel pharmaceuticals, inc. (RIGL) has a Price-To-Earnings (PE) ratio of 1.66 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
